The prevalence of non-vascular pulmonary manifestations in Takayasu's Arteritis patients: A Retrospective multi-centred Turkish cohort study.


Journal

Scandinavian journal of rheumatology
ISSN: 1502-7732
Titre abrégé: Scand J Rheumatol
Pays: England
ID NLM: 0321213

Informations de publication

Date de publication:
07 2022
Historique:
pubmed: 14 10 2021
medline: 29 6 2022
entrez: 13 10 2021
Statut: ppublish

Résumé

Takayasu's arteritis (TAK) is a rare vasculitis characterized by inflammation of intermediate- to large-size arteries. Although pulmonary artery involvement (PAI) is an expected finding in some TAK patients, data on non-vascular pulmonary involvement (NVPI) are limited. We aimed to investigate the frequency of NVPI, including parenchymal infiltration, nodules/cavities, pleural effusion, and haemorrhage, in TAK. We assembled a retrospective cohort of TAK patients from nine tertiary centres in Turkey. The demographics and clinical characteristics of patients were extracted from medical records and the imaging findings were evaluated for pulmonary manifestations. As of January 2021, 319 TAK patients (female/male 276/43; mean age 42.4 ± 13.5 years) were recruited. Eighty-two patients had cough and/or dyspnoea and four had haemoptysis as pulmonary symptoms. On computed tomography assessment, the overall frequency of NVPI was 7.2%; parenchymal infiltrations were present in 10 (3.1%), pleural effusion in eight (2.5%), nodules/cavities in six (1.9%), and pulmonary haemorrhage in four patients (1.3%). In the whole cohort, 10.3% of patients had pulmonary artery hypertension (PAH) and 5.6% had PAI. Among patients with PAH or PAI, the overall frequency of NVPI was significantly higher than in the rest of the group. In this TAK cohort from Turkey, we observed NVPI in 7.2% of patients, with parenchymal infiltrations being the most common, followed by pleural effusion. Notably, NVPI was more frequent in patients with PAH or PAI. Although not as common as PAI, NVPI should be kept in mind, especially in TAK patients with PAH or PAI.

Identifiants

pubmed: 34643164
doi: 10.1080/03009742.2021.1972535
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

304-308

Auteurs

A Yazici (A)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Kocaeli University, Kocaeli, Turkey.

S Kaymaz-Tahra (S)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Marmara University, Istanbul, Turkey.

O Ozdemir Isik (O)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Kocaeli University, Kocaeli, Turkey.

M Kara (M)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Ege University, Izmir, Turkey.

N Alpay-Kanitez (N)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Koç University, Istanbul, Turkey.

O Gerçik (O)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Katip Celebi University, Izmir, Turkey.

A Omma (A)

Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey.

S B Kocaer (SB)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Dokuz Eylul University, Izmir, Turkey.

K Kalkan (K)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Trakya University, Edirne, Turkey.

N S Yasar Bilgin (NS)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Osmangazi University, Eskisehir, Turkey.

K Aksu (K)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Ege University, Izmir, Turkey.

G Keser (G)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Ege University, Izmir, Turkey.

S Akar (S)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Katip Celebi University, Izmir, Turkey.

F Onen (F)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Dokuz Eylul University, Izmir, Turkey.

H Emmungil (H)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Trakya University, Edirne, Turkey.

T Kasifoglu (T)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Osmangazi University, Eskisehir, Turkey.

F Alibaz-Oner (F)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Marmara University, Istanbul, Turkey.

H Direskeneli (H)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Marmara University, Istanbul, Turkey.

A Cefle (A)

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Kocaeli University, Kocaeli, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH